Cancer in a drop: Advances in liquid biopsy in 2024
Roberto Borea(Antwerp University Hospital), Carolina Reduzzi(Cornell University), Shivahamy Maheswaran(University of Pennsylvania), Eleonora Nicolò(Cornell University), Diego de Miguel‐Pérez(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Letizia Pontolillo(Università Cattolica del Sacro Cuore), Angelo Dipasquale(IRCCS Humanitas Research Hospital), Pasquale Pisapia(University of Naples Federico II), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Erick Figueiredo Saldanha(Princess Margaret Cancer Centre), A. Ortega Franco(The Christie NHS Foundation Trust), Konstantinos Venetis(European Institute of Oncology), Nadia Ghazali(Princess Margaret Cancer Centre), Surbhi Singhal(International Society of Nephrology)
Cited by 31
Related Papers
FGFR a promising druggable target in cancer: Molecular biology and new drugs
|Critical Reviews in Oncology/Hematology|2017|203
Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy
|Breast Cancer Research|2019|182
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
|Expert Review of Molecular Diagnostics|2017|171
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
|Scientific Reports|2020|118
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
|Annals of Oncology|2023|103